SELENBP1 and atherosclerosis: Moreover, when subdividing the non-CAS individuals into ASCVD patients and non-ASCVD populations, serum SELENBP1 and VCL levels did not differ within the two subgroups but were evidently higher than those in the CAS group (Figure S2), further supporting the diagnostic specificity of serum SELENBP1 and VCL levels for CAS.